Trump Medicare drug pricing model may apply to only four companies after exemptions

The finalized Trump administration GLOBE Medicare drug-pricing rule may apply to as few as four manufacturers after exempting companies with separate most-favored-nation pricing deals, including agreements involving Pfizer, Eli Lilly and Novo Nordisk. HHS cut projected Medicare Part B savings from $11.9 billion in the proposal to $440 million over the model period, substantially reducing the program's fiscal impact. The exemptions lessen direct pricing-model risk for many large pharmaceutical companies, while limiting anticipated federal savings.

Analysis

The market implication is materially less adverse than the original proposal for large-cap pharma: the formal Medicare Part B pricing mechanism now appears too narrow to alter group-level earnings power for firms covered by separate White House arrangements. LLY and NVO should see the largest multiple relief because their valuation discounts are unusually sensitive to perceived U.S. pricing-policy duration, while PFE benefits more modestly given its lower growth and greater dependence on pipeline execution. The key second-order effect is that negotiated bilateral agreements may become the administration’s preferred tool, replacing broad-based statutory pricing risk with opaque, company-specific concessions.

Near term, this removes a potential downside catalyst rather than creating a major earnings upgrade; investors should not capitalize the full difference between prior and revised government savings estimates until the terms, duration, and product scope of the bilateral agreements are disclosed. Over the next 1-3 months, watch whether exempt companies face offsetting commitments on list prices, Medicaid rebates, domestic manufacturing, or volume guarantees. If those commitments are largely commercial rather than price-based, branded-drug gross-margin risk is lower than consensus had assumed; if they include future-price caps on high-growth therapies, the risk merely shifts beyond the model period.

Contrarian view: the apparent relief may be more valuable for LLY/NVO than PFE, but it also strengthens the political precedent for selective negotiations targeted at the most visible drugs. That creates a long-duration policy overhang for obesity and diabetes franchises precisely because their Medicare exposure grows with utilization. The remaining four manufacturers are an information vacuum: identification could create sharp single-name downside, especially for companies with concentrated Part B oncology, immunology, or infused-drug revenue.

Key Decisions for Investors

• Tactically add to LLY and NVO on weakness over the next 1-4 weeks, but size as a policy-volatility trade rather than an earnings revision: the narrowed mechanism supports multiple stabilization, while obesity-volume, supply, and bilateral-agreement terms remain the dominant 6-18 month risks.
• Prefer a relative-value long LLY / short PFE over a broad pharma beta trade for a 3-6 month horizon. LLY has greater pricing-risk relief and higher organic growth; invalidate if LLY issues material U.S. net-price or Medicare-access concessions, or if obesity prescription growth decelerates materially.
• Do not initiate a directional APP or SMCI position from this development; neither has a discernible economic linkage. Treat their inclusion as non-informative rather than evidence of a cross-sector signal.
• Set an event-driven alert for disclosure of the four non-exempt manufacturers and the underlying White House agreement terms. A company with more than 10% of sales tied to Medicare Part B-administered products and no exemption would be a candidate for a short or put-spread hedge after verifying product-level exposure.
• For existing pharma longs, use the next earnings cycle to test the thesis: reduce exposure if management guides to incremental U.S. gross-to-net pressure or frames government agreements as recurring price concessions rather than one-time access arrangements.